Developing a Qualification and Verification Strategy for Digital Tissue Image Analysis in Toxicological Pathology.

Journal: Toxicologic pathology
Published Date:

Abstract

Digital tissue image analysis is a computational method for analyzing whole-slide images and extracting large, complex, and quantitative data sets. However, as with any analysis method, the quality of generated results is dependent on a well-designed quality control system for the entire digital pathology workflow. Such system requires clear procedural controls, appropriate user training, and involvement of specialists to oversee key steps of the workflow. The toxicologic pathologist is responsible for reporting data obtained by digital image analysis and therefore needs to ensure that it is correct. To accomplish that, they must understand the main parameters of the quality control system and should play an integral part in its conception and implementation. This manuscript describes the most common digital tissue image analysis end points and potential sources of analysis errors. In addition, it outlines recommended approaches for ensuring quality and correctness of results for both classical and machine-learning based image analysis solutions, as adapted from a recently proposed Food and Drug Administration regulatory framework for modifications to artificial intelligence/machine learning-based software as a medical device. These approaches are beneficial for any type of toxicopathologic study which uses the described end points and can be adjusted based on the intended use of the image analysis solution.

Authors

  • Aleksandra Zuraw
    Definiens AG, Munich, 80636, Germany.
  • Michael Staup
    Pathology Department, 25913Charles River Laboratories, Durham, NC, USA.
  • Robert Klopfleisch
    Institute of Veterinary Pathology, Freie Universität Berlin, Berlin, Germany.
  • Famke Aeffner
    Amgen Research, Comparative Biology and Safety Sciences, Amgen Inc., South San Francisco, CA, USA.
  • Danielle Brown
    Pathology Department, 25913Charles River Laboratories, Durham, NC, USA.
  • Thomas Westerling-Bui
    Aiforia Inc, Cambridge, MA, USA.
  • Daniel Rudmann
    Pathology Department, 25913Charles River Laboratories, Ashland, OH, USA.